Corbus Pharmaceuticals
CRBP
107 hedge funds and large institutions have $486M invested in Corbus Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 41 funds opening new positions, 23 increasing their positions, 24 reducing their positions, and 15 closing their positions.
173% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 15
100% more funds holding in top 10
Funds holding in top 10: 3 → 6 (+3)
45% more capital invested
Capital invested by funds: $335M → $486M (+$151M)
30% more funds holding
Funds holding: 82 → 107 (+25)
19.27% more ownership
Funds ownership: 81.31% → 100.59% (+19%)
4% less repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 24
22% less call options, than puts
Call options by funds: $1.19M | Put options by funds: $1.52M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$22.7M |
| 2 |
State Street
Boston,
Massachusetts
|
+$17.1M |
| 3 |
DGM
Darwin Global Management
St. Helier,
Jersey
|
+$13.7M |
| 4 |
SCM
Sio Capital Management
New York
|
+$9.47M |
| 5 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$9.07M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$20.4M |
| 2 |
IC
Ikarian Capital
Dallas,
Texas
|
-$10.5M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
-$5.71M |
| 4 |
PM
Prosight Management
Dallas,
Texas
|
-$3.95M |
| 5 |
Barclays
London,
United Kingdom
|
-$3.93M |
CRBP Hedge Fund Activity: Q2 2024 in Review
107 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Corbus Pharmaceuticals (CRBP) for Q2 2024, worth a combined $486M — up 45% from $335M a quarter earlier.
Buyers outnumbered sellers: 41 funds opened new CRBP positions and 15 closed out — a net gain of 26 holders — while 23 added to existing stakes and 24 trimmed.
The largest buyer was BlackRock, adding an estimated $22.7M. The largest seller was Point72 Asset Management, cutting an estimated $20.4M.
- 107 institutional investors held Corbus Pharmaceuticals (CRBP) as of Q2 2024, up from 82 in Q1 2024.
- Funds reported $486M of Corbus Pharmaceuticals stock for Q2 2024, up 45% quarter-over-quarter.
- 41 funds opened new Corbus Pharmaceuticals positions in Q2 2024 and 15 closed out, a net change of +26 holders.
- The largest Corbus Pharmaceuticals buyer in Q2 2024 was BlackRock, an estimated $22.7M added.
- The largest Corbus Pharmaceuticals seller in Q2 2024 was Point72 Asset Management, an estimated $20.4M sold.
Based on aggregated 13F filings for Q2 2024.